Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998497 | 0.87 | CHRNA4 (0.45) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19012673 | 0.82 | CHRNA4 (0.52) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14731489 | 0.78 | CHRNA4 (0.56) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20138338 | 0.74 | RIPK1 (0.52) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17665105 | 0.73 | KDM4E (0.45) | TBK1VNN1 | |
| SCHEMBL20152893 | 0.72 | RIPK1 (0.55) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22874982 | 0.71 | CHRNA4 (0.51) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20935043 | 0.71 | CHRNA4 (0.48) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3333912 | 0.71 | CHRNA4 (0.82) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23579315 | 0.71 | SMN1; SMN2 (0.33) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | CHRNA4 4694/4885CHRNB2 4074/4885CHRNB4 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.